The All Wales Medicines Strategy Group started the assessment of ivacaftor (Kalydeco) as soon as the drug company formally engaged with the appraisal process. This process is recognised to be robust and normally takes about 21 weeks to allow all parties, including patient organisations such as the Cystic Fibrosis Trust, to submit their comments. The final appraisal decision for Kalydeco is scheduled to be reached at a public meeting on 8th May 2013.
More top news
Cold weather is again on the way for the UK. Colder conditions will spread south, bringing a mixture of sunny spells and snow showers
Siarad cymraeg McBusted? Well you will be by April! Pop band get a lesson in Welsh ahead of their Cardiff gig
Clear spells across southern and eastern parts will lead to a chilly night with a local frost possible